Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

被引:92
|
作者
Saint, F [1 ]
Patard, JJ
Maille, P
Soyeux, P
Hoznek, A
Salomon, L
Abbou, CC
Chopin, DK
机构
[1] Hop Henri Mondor, Dept Urol, Grp Etud Tumeurs Urol, F-94010 Creteil, France
[2] Hop Henri Mondor, EMI 99 09, INSERM, Dept Urol, F-94010 Creteil, France
来源
JOURNAL OF UROLOGY | 2002年 / 167卷 / 01期
关键词
bladder; bladder neoplasms; Mycobacterium bovis; cytokines; interleukin-2;
D O I
10.1016/S0022-5347(05)65469-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Interleukin (IL)-2 and interferon-gamma are released during T helper 1 lymphocyte responses, while IL-10 is released during T helper 2 responses. We evaluated the prognostic value of urinary IL-2, interferon-gamma and IL-10 levels in patients with superficial bladder cancer treated with bacillus Calmette-Guerin (BCG) instillation Methods: Urinary IL-2, interferon-gamma and IL-10 were measured by enzyme-linked immunosorbent assay in 37 patients receiving BCG for stages Ta/T1 superficial bladder cancer, and carcinoma in situ. Measurements were made after instillations 5 and 6 during a course of 6 weekly instillations of 150 mg. BCG, Pasteur strain. Correlations of cytokine levels with the clinical outcome were evaluated using the log rank test Results: Median followup was 29 months. Patients with urinary IL-2 less than 27 pg./mu mol. creatinine were significantly more likely to have recurrences than those with higher values (log rank test p = 0.0009). Urinary IL-10 and interferon-gamma levels had no apparent impact on the risk of recurrence or progression Conclusion: Urinary IL-2 levels may serve to identify patients at risk for bladder cancer recurrence after a single course of BCG and, thus, to tailor individual treatment.
引用
下载
收藏
页码:364 / 367
页数:4
相关论文
共 50 条
  • [31] Stage T1 adenocarcinoma of the urinary bladder -: Complete response after transurethral resection and intravesical bacillus Calmette-Guerin
    Holmäng, S
    Aldenborg, F
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 (02): : 141 - 143
  • [32] Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guerin instillations for superficial bladder cancer
    Kaneko, T
    Fujita, K
    Homma, Y
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (03) : 294 - 295
  • [33] Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin is not indicated for superficial bladder cancer
    Tozawa, K
    Okamura, T
    Sasaki, S
    Kawai, N
    Ito, Y
    Hayashi, Y
    Kohri, K
    UROLOGIA INTERNATIONALIS, 2001, 67 (04) : 289 - 292
  • [34] Bacillus Calmette-Guerin in the management of superficial bladder cancer
    Kapoor, Rakesh
    Vijjan, Vivek
    Singh, Pratipal
    INDIAN JOURNAL OF UROLOGY, 2008, 24 (01) : 72 - 76
  • [35] Intravesical Bacillus Calmette-Guerin for the treatment of superficial bladder cancer following hematopoietic stem cell transplantation
    Petropoulou, Anna D.
    Lapusan, Simona
    Marie, Jean-Pierre
    Rio, Bernard
    LEUKEMIA & LYMPHOMA, 2008, 49 (08) : 1627 - 1629
  • [36] DOSE-RESPONSE OF BACILLUS CALMETTE-GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER-CANCER
    MORALES, A
    NICKEL, JC
    WILSON, JWL
    JOURNAL OF UROLOGY, 1992, 147 (05): : 1256 - 1258
  • [37] CLINICAL-STUDY OF PROGNOSTIC FACTORS OF SUPERFICIAL BLADDER-CANCER TREATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN
    SHINKA, T
    HIRANO, A
    UEKADO, Y
    OHKAWA, T
    BRITISH JOURNAL OF UROLOGY, 1990, 66 (01): : 35 - 39
  • [38] IMMUNE-REACTIONS IN PATIENTS WITH SUPERFICIAL BLADDER-CANCER AFTER INTRADERMAL AND INTRAVESICAL TREATMENT WITH BACILLUS CALMETTE-GUERIN
    VANDERMEIJDEN, APM
    STEERENBERG, PA
    VANHOOGSTRAATEN, IMW
    KERCKHAERT, JA
    SCHREINEMACHERS, LMH
    HARTHOORNLASTHUIZEN, EJ
    HAGENAARS, AM
    DEJONG, WH
    DEBRUIJNE, FMJ
    RUITENBERG, EJ
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1989, 28 (04) : 287 - 295
  • [39] MANAGEMENT OF STAGE-T1 SUPERFICIAL BLADDER-CANCER WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY - COMMENTS
    LAMM, DL
    JOURNAL OF UROLOGY, 1992, 148 (03): : 801 - 801
  • [40] INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR CARCINOMA INSITU OF THE URINARY-BLADDER
    WALLACE, DMA
    BRITISH JOURNAL OF CANCER, 1991, 63 (05) : 831 - 831